AMAG Pharmaceuticals
Develops and delivers innovative medicines across a range of therapeutic areas.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD1b (Public information from Oct 2020)
Share price
$13.75 AMAG
Lexington Kentucky (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 494m | 472m | 327m | 246m | 239m | 227m |
| % growth | - | - | (4 %) | (31 %) | (25 %) | (3 %) | (5 %) |
| EBITDA | - | 166m | 97.0m | (114m) | 5.0m | 26.0m | 39.0m |
| % EBITDA margin | - | 34 % | 21 % | (35 %) | 2 % | 11 % | 17 % |
| Profit | - | (201m) | (68.0m) | (468m) | (37.0m) | 2.0m | (1.0m) |
| % profit margin | - | (41 %) | (14 %) | (143 %) | (15 %) | 1 % | - |
| R&D budget | 69.3m | 69.3m | 42.9m | 63.8m | - | - | - |
| R&D % of revenue | - | 14 % | 9 % | 20 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | $175m | Post IPO Equity |
* | N/A | $300m | Post IPO Convertible |
$647m Valuation: $647m 2.0x EV/LTM Revenues -5.7x EV/LTM EBITDA | Acquisition | ||
| Total Funding | - | ||
Related Content
Recent News about AMAG Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by AMAG Pharmaceuticals
Edit
ACQUISITION by AMAG Pharmaceuticals Dec 2018
ACQUISITION by AMAG Pharmaceuticals Sep 2014